Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis
In well-characterised MS patients treated with interferon β, fingolimod or natalizumab, clinicodemographic information provides modest prognostic value; however, NfL adds minimal incremental utility.
Authors
- Charles Benjamin Malpas (ORCID: https://orcid.org/0000-0003-0534-3718)
- Sifat Sharmin (ORCID: https://orcid.org/0000-0001-7294-9723)
- Nahid Moradi (ORCID: https://orcid.org/0000-0001-6253-4487)
- Ingrid Kochum
- David Leppert (ORCID: https://orcid.org/0000-0001-6172-801X)
- Eva Havrdová (ORCID: https://orcid.org/0000-0002-9543-4359)
- Pavlína Kleinová (ORCID: https://orcid.org/0000-0002-5911-936X)
- Jan Hillert
- Pascal Benkert
- Tomas Olsson
- Katherine Buzzard
- Dana Horáková
- Bruce V. Taylor
- Jens Kuhle
- Ali Manouchehrinia
- Michael Barnett
- Trevor J. Kilpatrick
- Tomas Kalincik
- Tomas Uher
Institutions
- The University of Sydney (AU)
- University of Tasmania (AU)
- The Royal Melbourne Hospital (AU)
- Karolinska University Hospital (SE)
- Box Hill Hospital (AU)
- The University of Melbourne (AU)
- University of Basel (CH)
- Charles University (CZ)
- Florey Institute of Neuroscience and Mental Health (AU)
- Victorian Curriculum and Assessment Authority (AU)
- University Hospital of Basel (CH)
- Karolinska Institutet (SE)
- UNSW Sydney (AU)
- Cooperative Trials Group for Neuro-Oncology (AU)
- General University Hospital in Prague (CZ)
- Australian Psychological Society (AU)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1111/ene.70505
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical Research Council
- National Health and Medical Research Council